We expected the word "ketamine" to split our survey respondents into fans and opponents. It did not. What we found instead was a large middle full of hesitation, and a strong, widely shared demand for one particular kind of reassurance: the FDA's.
This is the story of those two findings, what they may mean for people who are skeptical of ketamine therapy, and what they cannot tell us.
Our source
The numbers come from a poll we paid for: 443 people aged 18 through 64, all residents of a ten-state stretch of the Midwest, reached through a consumer panel that closed June 23, 2026. The totals below cover everyone and come from the validated, final data.
Finding one: doubt is widespread, hostility is not
Here is how respondents reacted on first hearing about ketamine therapy for depression or PTSD:
- Wary, yet willing to listen: 34 percent
- Doubtful: 21 percent (the survey's word was skeptical)
- Hopeful, or simply curious: 18 percent
- First time hearing of it: 18 percent
- Against it: 9 percent
Only about one respondent in eleven reacted negatively. But pure enthusiasm was rare too. The most common posture was a guarded one, and skepticism was the second most common answer outright. If you add skeptical and negative together, 31 percent of the sample started from doubt or opposition. If you add the two open answers, 51 percent were willing to hear more.
That is a picture of a public that has not made up its mind. Most people are waiting for a reason to trust, or a reason not to.
Finding two: the FDA stamp carries real weight
Another question asked respondents how heavily FDA approval would count if they were deciding on the treatment. For 19 percent, nearly one in five, approval alone would decide it. Another 40 percent, two respondents in five, rated it a big factor. Twenty-seven percent said some factor, and 14 percent said it would not matter.
Taken together, those two answers mean 59 percent of our respondents would weigh FDA approval heavily. Among the trust signals we asked about, only insurance coverage performed at a similar level, with 65 percent calling it deciding or big.
What we can and cannot connect
It is tempting to say that skeptics are the ones demanding FDA approval. This article does not break that out. Our data does not show how the skeptical respondents answered the FDA question, and making up that link would be exactly the kind of invented number we refuse to publish.
Here is what the totals do support: throughout the sample, doubt about ketamine therapy and a strong preference for FDA approval exist side by side at high levels. In a population where caution is the norm, regulatory review is one of the few reassurances a clear majority says it values.
There is one more wrinkle worth noting. When respondents had to rank what matters most in choosing a provider, the FDA stamp slipped. Of the sample, 85 percent put coverage among their two leading priorities and 43 percent put a nearby location there, while FDA approval made it for about a quarter. Our reading is that approval acts as a threshold people expect a treatment to clear, after which cost and distance decide where they actually go.
Why this matters for anyone doubtful about ketamine
If you are skeptical, the FDA question is a useful tool, because "ketamine therapy" is not one thing.
Spravato, a nasal spray form of esketamine, carries FDA approval for adults whose earlier treatments left their depression in place, and each dose happens at a certified site with staff observing before and after. Brain Recovery Centers explains what a Spravato appointment involves for readers who want specifics. When clinics infuse generic ketamine for depression, they are using an anesthetic off-label. At-home ketamine, often through telehealth and sometimes compounded, has less oversight still.
A skeptic does not need to accept or reject all of these at once. Asking which one is on the table, and what its FDA status is, lets you apply your doubt precisely.
The awareness gap makes this harder
Here is the complication. The approved product is almost unknown. Spravato was entirely unfamiliar to 73 percent of our respondents; 21 percent had heard the name and knew nothing else, which left a sliver of 6 percent able to describe it.
So people who care about FDA approval may be judging "ketamine" as a single category, without knowing that one version has passed the review they value. That is not a reason to change your mind. It is a reason to make sure your doubt is aimed at the right target.
And a drug-free option most people have not heard of
Some skeptics are doubtful about any new medication, not just ketamine. For them, another finding is relevant. Avoiding drugs mattered to 64 percent of those surveyed, yet only 25 percent knew TMS. It needs no medication, just a magnetic coil applied to the scalp, and the FDA has cleared its devices for adults whose depression outlasted antidepressants.
Who people trust to sort it out
On whose word would sway them, respondents gave their own doctor 74 percent, a friend or relative 18 percent, ads 2 percent, and podcasters just 1 percent. For a skeptic, that is good news. The person best placed to explain regulatory status and your own suitability is the person most people already trust.
What to take from this
- If you are skeptical, you are part of a large group, and caution is reasonable.
- Ask which form of ketamine is being discussed and what its FDA status is.
- Ask about drug-free options such as TMS or therapy if avoiding medication matters to you.
- Bring your questions to a clinician with your records in front of them; fit is their judgment to make.
- Do not stop a current medication on your own while you decide.
Doubting a treatment is never a reason to go without support. If suicide is on your mind, 988 connects you by call or text to the Suicide and Crisis Lifeline.
Methodology
Pollfish study 395586438 drew its 443 completes from the Pollfish consumer panel before closing on June 23, 2026. Participants, every one aged 18 to 64, resided in Missouri, Wisconsin, Nebraska, Indiana, Kansas, Minnesota, Iowa, Ohio, Illinois or Oklahoma; each had to accept a consent screener to continue. Figures cover the whole sample. Pollfish has finished validating them, so they are final. The publisher is the study's sponsor and paid for it.